D. Keefe

Publications104
h-index28
Citations3,365
Highly Influential Citations105
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Winkle
  • 218 Publications, 13,116 Citations
  • D. Harrison
  • 527 Publications, 21,657 Citations
  • M. Josephson
  • 752 Publications, 39,707 Citations
  • J. Mason
  • 295 Publications, 19,831 Citations
  • Publications
  • Influence
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
OBJECTIVES This dose-ranging study evaluated the antihypertensive efficacy and tolerability of aliskiren in patients with mild-to-moderate hypertension. BACKGROUND Low blood pressure (BP) control… Expand
  • 265
  • 13
  • PDF
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
Background—Loss of negative feedback inhibition of renin release during chronic treatment with an angiotensin-converting enzyme (ACE) inhibitor leads to a compensatory rise in renin secretion and… Expand
  • 377
  • 12
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial
Objectives This double-blind study compared long-term efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren and the angiotensin-converting enzyme inhibitor ramipril alone and… Expand
  • 158
  • 11
Trastuzumab‐associated cardiotoxicity
Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the HER2 protein. Cardiotoxicity has been reported to occur with… Expand
  • 300
  • 9
Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension
Current guidelines from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommend first-line treatment with a thiazide diuretic but do not… Expand
  • 158
  • 6
  • PDF
Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.
The antihypertensive efficacy and safety of the direct renin inhibitor aliskiren were assessed in a pooled analysis of data from seven randomized, multicenter studies. Data were available for 7,045… Expand
  • 102
  • 5
Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients… Expand
  • 81
  • 5
Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial
Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind,… Expand
  • 73
  • 5
Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients
J Clin Hypertens (Greenwich). 2011;13:506–516. ©2011 Wiley Periodicals, Inc.
  • 23
  • 5
9.9 Aliskiren, a Novel Renin Inhibitor, is Well Tolerated and Has Sustained BP-Lowering Effects Alone or in Combination with HCTZ During Long-Term (52 Weeks) Treatment of Hypertension
  • 24
  • 4